Abstract Details

Title Olfactory dysfunction in incidental Lewy body disease and Parkinson's disease: An update

Topic Movement Disorders

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 5-005

Objective Using a larger sample size compared to our previous study, we evaluated the relationship between olfactory dysfunction based on the University of Pennsylvania Smell Identification Test (UPSIT) to the clinicopathological findings in PD (n=41), incidental Lewy Body Disease (n=47), and controls with no neurodegenerative disease (n=137).

Background Measuring olfactory dysfunction shows promise as one of a number of non-motor biomarkers that can be used to detect clinically-manifest and prodromal Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), and to differentiate these from non-synucleinopathies.

Design/Methods This study was conducted through the Arizona Studying of Aging and Neurodegenerative Disease (AZSAND). We selected individuals who had an UPSIT score completed antemortem and were clinicopathologically diagnosed with PD, ILBD, or control. Various measures included density of Lewy type synucleinopathy (aSyn) in the olfactory bulb and tract as well as connected mesial temporal lobe structures. Cases and controls were analyzed using one-way analysis of variance with pairwise contrasts.

Results Compared to controls (mean 27.8, SD 6.0), the mean UPSIT scores were lower for PD (15.8, SD 6.0, p<.001) and ILBD (24.1, SD 8.6, p<.001). The sensitivity for detecting ILBD from controls based on a cutoff score of <23 (23/47) was 48.9%. The specificity for detecting a control was 79.6% with a cutoff >23 (109/137)

Conclusions These findings replicate, with a larger sample size, our previously published finding that individuals with autopsy confirmed PD and ILBD have significantly lower UPSIT scores compared to controls. These data add to the growing body of evidence supporting early olfactory dysfunction as a prodromal biomarker for the risk of developing Parkinson’s disease, and also supporting ILBD as a prodromal Lewy body disorder.

Authors/Disclosures
Shemonti Hasan, MD PRESENTER	Dr. Hasan has nothing to disclose.
Charles H. Adler, MD, PhD, FAAN (Mayo Clinic Arizona)	Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Adler has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CND Life Sci. Dr. Adler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Precon. Dr. Adler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. The institution of Dr. Adler has received research support from NIH. The institution of Dr. Adler has received research support from Michael J. Fox Foundation. The institution of Dr. Adler has received research support from Arizona Biomedical Research Commission. Dr. Adler has received publishing royalties from a publication relating to health care.
Cynthia M. Stonnington, MD (Mayo Clinic Arizona)	Dr. Stonnington has nothing to disclose.
Geidy Serrano	Geidy Serrano has nothing to disclose.
	No disclosure on file
Holly A. Shill, MD, FAAN (Barrow Neurology Clinics)	Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage Biogen. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for KeifeRx. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Praxis Precision Medicine. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl Inc. Dr. Shill has received personal compensation in the range of $0-$499 for serving as a Consultant for Boston Scientific. Dr. Shill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America.
Shyamal Mehta, MD, PhD, FAAN (Mayo Clinic, Arizona)	Dr. Mehta has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Adamas Pharma. Dr. Mehta has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Mehta has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for CNS Ratings.
Thomas Beach (Banner Sun Health Research Institute)	Thomas Beach has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vivid Genomics. Thomas Beach has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche Diagnostics. The institution of Thomas Beach has received research support from National Institutes of Health. The institution of Thomas Beach has received research support from Michael J Fox Foundation . The institution of Thomas Beach has received research support from State of Arizona.
Erika Driver-Dunckley, MD, FAAN	Dr. Driver-Dunckley has nothing to disclose.

��ɫ��

��ɫ��